Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2015 Sep 9

PMID 26346901

Citations 63

Authors

Andrea de Bartolomeis

Carmine Tomasetti

Felice Iasevoli

Affiliations

Soon will be listed here.

Abstract

Dopamine partial agonism and functional selectivity have been innovative strategies in the pharmacological treatment of schizophrenia and mood disorders and have shifted the concept of dopamine modulation beyond the established approach of dopamine D2 receptor (D2R) antagonism. Despite the fact that aripiprazole was introduced in therapy more than 12 years ago, many questions are still unresolved regarding the complexity of the effects of this agent on signal transduction and intracellular pathways, in part linked to its pleiotropic receptor profile. The complexity of the mechanism of action has progressively shifted the conceptualization of this agent from partial agonism to functional selectivity. From the induction of early genes to modulation of scaffolding proteins and activation of transcription factors, aripiprazole has been shown to affect multiple cellular pathways and several cortical and subcortical neurotransmitter circuitries. Growing evidence shows that, beyond the consequences of D2R occupancy, aripiprazole has a unique neurobiology among available antipsychotics. The effect of chronic administration of aripiprazole on D2R affinity state and number has been especially highlighted, with relevant translational implications for long-term treatment of psychosis. The hypothesized effects of aripiprazole on cell-protective mechanisms and neurite growth, as well as the differential effects on intracellular pathways [i.e. extracellular signal-regulated kinase (ERK)] compared with full D2R antagonists, suggest further exploration of these targets by novel and future biased ligand compounds. This review aims to recapitulate the main neurobiological effects of aripiprazole and discuss the potential implications for upcoming improvements in schizophrenia therapy based on dopamine modulation beyond D2R antagonism.

Citing Articles

Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas.

Mignone E, Jukes A, Valentine R, Allison R, De Sousa S Endocr Oncol. 2025; 5(1):e240065.

PMID: 39906305 PMC: 11792114. DOI: 10.1530/EO-24-0065.

ChangPu YuJin Tang improves Tourette disorder symptoms by modulating amino acid neurotransmitters in IDPN model rats.

Lu M, Shi Z, Shang J, Gao L, Gao L, Gao W Metab Brain Dis. 2024; 39(8):1543-1558.

PMID: 39312065 DOI: 10.1007/s11011-024-01411-x.

Catatonia.

Hirjak D, Rogers J, Wolf R, Kubera K, Fritze S, Wilson J Nat Rev Dis Primers. 2024; 10(1):49.

PMID: 39025858 DOI: 10.1038/s41572-024-00534-w.

An experimentally validated approach to automated biological evidence generation in drug discovery using knowledge graphs.

Sudhahar S, Ozer B, Chang J, Chadwick W, ODonovan D, Campbell A Nat Commun. 2024; 15(1):5703.

PMID: 38977662 PMC: 11231212. DOI: 10.1038/s41467-024-50024-6.

Neutrophil-Lymphocyte Ratio Values in Schizophrenia: A Comparison between Oral and Long-Acting Antipsychotic Therapies.

Messina A, Bella F, Maccarone G, Rodolico A, Signorelli M Brain Sci. 2024; 14(6).

PMID: 38928602 PMC: 11201385. DOI: 10.3390/brainsci14060602.

References

Tomasetti C, Dellaversano C, Iasevoli F, de Bartolomeis A . Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience. 2007; 150(1):144-58. DOI: 10.1016/j.neuroscience.2007.08.022. View

Bruins Slot L, De Vries L, Newman-Tancredi A, Cussac D . Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol. 2006; 534(1-3):63-70. DOI: 10.1016/j.ejphar.2006.01.027. View

Lyford G, Yamagata K, Kaufmann W, Barnes C, Sanders L, Copeland N . Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron. 1995; 14(2):433-45. DOI: 10.1016/0896-6273(95)90299-6. View

Zhang J, Kowal D, Nawoschik S, Lou Z, Dunlop J . Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol. 2005; 71(4):521-9. DOI: 10.1016/j.bcp.2005.11.007. View

Inoue A, Seto M, Sugita S, Hide I, Hirose T, Koga N . Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Brain Res Mol Brain Res. 1998; 55(2):285-92. DOI: 10.1016/s0169-328x(98)00009-6. View

Bartoszyk G, Harting J, Minck K . Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist. J Pharmacol Exp Ther. 1996; 276(1):41-8. View

Segnitz N, Ferbert T, Schmitt A, Gass P, Gebicke-Haerter P, Zink M . Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain. Psychopharmacology (Berl). 2011; 217(1):127-42. DOI: 10.1007/s00213-011-2262-z. View

Ito H, Takano H, Arakawa R, Takahashi H, Kodaka F, Takahata K . Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. PLoS One. 2012; 7(9):e46488. PMC: 3460902. DOI: 10.1371/journal.pone.0046488. View

Jordan S, Johnson J, Regardie K, Chen R, Koprivica V, Tadori Y . Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 31(2):348-56. DOI: 10.1016/j.pnpbp.2006.09.007. View

10.

Nguyen C, Rosen J, Bota R . Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities. Prim Care Companion CNS Disord. 2013; 14(5). PMC: 3583771. DOI: 10.4088/PCC.12m01386. View

11.

Kara E, Lin H, Svensson K, Johansson A, Strange P . Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor. Br J Pharmacol. 2010; 161(6):1343-50. PMC: 3000658. DOI: 10.1111/j.1476-5381.2010.01010.x. View

12.

Rosenheck R, Krystal J, Lew R, Barnett P, Fiore L, Valley D . Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011; 364(9):842-51. DOI: 10.1056/NEJMoa1005987. View

13.

Cheng M, Liao D, Hsiung C, Chen C, Liao Y, Chen C . Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int J Neuropsychopharmacol. 2007; 11(2):207-16. DOI: 10.1017/S1461145707008048. View

14.

Feng M, Siersma P, Strenkoski C, Wright D . Sensitive high-performance liquid chromatographic method for a dopamine receptor agonist, CI-1007, and its metabolite PD 147693 in monkey plasma. J Chromatogr B Biomed Appl. 1995; 665(1):193-9. DOI: 10.1016/0378-4347(94)00506-z. View

15.

Tomasetti C, DellAversano C, Iasevoli F, Marmo F, de Bartolomeis A . The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 35(1):184-97. DOI: 10.1016/j.pnpbp.2010.10.025. View

16.

Lamba J, Lin Y, Schuetz E, Thummel K . Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002; 54(10):1271-94. DOI: 10.1016/s0169-409x(02)00066-2. View

17.

Iyer R, Davis M, Juneau P, Giordani A . Brain extracellular levels of the putative antipsychotic CI-1007 and its effects on striatal and nucleus accumbens dopamine overflow in the awake rat. J Pharm Pharmacol. 1998; 50(10):1147-53. DOI: 10.1111/j.2042-7158.1998.tb03326.x. View

18.

Newman-Tancredi A, Cussac D, Audinot V, Nicolas J, De Ceuninck F, Boutin J . Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002; 303(2):805-14. DOI: 10.1124/jpet.102.039875. View

19.

Kilts J, Connery H, Arrington E, Lewis M, Lawler C, Oxford G . Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther. 2002; 301(3):1179-89. DOI: 10.1124/jpet.301.3.1179. View

20.

Rung J, Rung E, Helgeson L, Johansson A, Svensson K, Carlsson A . Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm (Vienna). 2008; 115(6):899-908. DOI: 10.1007/s00702-008-0038-3. View